Balance Sheet
Accounts PayablesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Viking Therapeutics (VKTX) Retained Earnings: 2014-2024

Historic Retained Earnings for Viking Therapeutics (VKTX) over the last 11 years, with Dec 2024 value amounting to -$487.9 million.

  • Viking Therapeutics' Retained Earnings fell 52.46% to -$689.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$689.9 million, marking a year-over-year decrease of 52.46%. This contributed to the annual value of -$487.9 million for FY2024, which is 29.10% down from last year.
  • Latest data reveals that Viking Therapeutics reported Retained Earnings of -$487.9 million as of FY2024, which was down 29.10% from -$377.9 million recorded in FY2023.
  • Over the past 5 years, Viking Therapeutics' Retained Earnings peaked at -$168.2 million during FY2020, and registered a low of -$487.9 million during FY2024.
  • Over the past 3 years, Viking Therapeutics' median Retained Earnings value was -$377.9 million (recorded in 2023), while the average stood at -$386.0 million.
  • Data for Viking Therapeutics' Retained Earnings shows a maximum YoY crashed of 32.69% (in 2021) over the last 5 years.
  • Viking Therapeutics' Retained Earnings (Yearly) stood at -$168.2 million in 2020, then slumped by 32.69% to -$223.2 million in 2021, then tumbled by 30.86% to -$292.0 million in 2022, then decreased by 29.41% to -$377.9 million in 2023, then declined by 29.10% to -$487.9 million in 2024.